Predicting outcome in patients with thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4673-4675

  Ross, Douglas S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HIGH RISK PATIENT; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; NOMOGRAM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR RECURRENCE;

FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; THYROID NEOPLASMS;

EID: 84889763131     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3989     Document Type: Review

References (16)

1. National Cancer Institute. SEER Cancer Statistics Review 1975- 2010. http://seer.cancer.gov/csr/1975-2010/results-merged/sect-26-thyroid.pdf.
2. National Cancer Institute. SEER Cancer Statistics Fact Sheets: Thyroid Cancer. http://seer.cancer.gov/statfacts/html/thyro.html.
3. AJCC Cancer Staging Manual. 7th ed. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. New York: Springer- Verlag; 2010.
4. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1057.
5. Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract. 2007;13:521-533.
6. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61:978-996.
7. Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399-407.
8. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13:498-512.
9. Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22: 1144-1152.
10. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19: 1167-1214.
11. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341-1349.
12. Pathak KA, Mazurat A, Lambert P, Klonisch TC, Nason RW. Prognostic nomograms to predict oncological outcome of thyroid cancers. J Clin Endocrinol Metab. 2013;98:4768-4775.
13. Memorial Sloan-Kettering Cancer Center. Prediction tools. http://nomograms.mskcc.org/Prostate/PreTreatment.aspx.
14. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31:468-474.
15. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565-612.
16. TuttleRM.Differentiated thyroid cancer: Clinicopathologic staging. In: Basow DS, ed. Waltham, MA: UpToDate; 2013.